How Therapeutic Plasma Exchange Reduces Biological Age

For decades, Dr. Dobri Kiprov has treated patients with therapeutic plasma exchange for conditions ranging from autoimmune disorders to Alzheimer's disease. Over the course of more than 15,000 treatments, he observed something that the published literature hadn't yet confirmed: patients weren't just improving in their specific condition. They were reporting changes that suggested something more fundamental was shifting. More energy, clearer thinking, better sleep, reduced inflammation markers across the board.

In 2022, that clinical intuition met hard science.

The GeroScience Study: First Clinical Evidence

A collaborative study between UC Berkeley and Global Apheresis, published in GeroScience in 2022, provided the first clinical evidence that therapeutic plasma exchange measurably reduces human biological age.

Led by first author Daehwan Kim of UC Berkeley's Conboy Lab, with Dr. Kiprov as co-first author, the study examined what happens to validated aging biomarkers after a course of TPE. Using established epigenetic clocks including the Horvath and GrimAge models, the researchers measured biological age before and after plasma exchange.

The findings were striking: participants showed a biological age reduction of one to three years, as measured by these validated clocks. The old, damaged plasma, carrying inflammatory proteins, oxidized albumin, and aging-associated molecules, was replaced with fresh albumin solution, and the body's biological markers responded accordingly.

This wasn't a theoretical projection or an animal model. It was measured in human patients undergoing the same therapeutic plasma exchange protocols that Dr. Kiprov has refined over four decades of clinical practice.

Why Plasma Ages — And What Replacement Does

To understand why this works, it helps to understand what accumulates in aging plasma.

As we age, the liquid component of our blood becomes increasingly burdened. Inflammatory cytokines rise. Albumin, the most abundant protein in plasma and one of the body's most important antioxidants, becomes oxidized and glycated, losing its protective function. Pro-aging signaling molecules accumulate, while regenerative factors decline.

These circulating molecules are increasingly recognized as primary drivers of biological aging. They don't just reflect aging; they actively promote it, signaling deterioration to every cell and tissue they reach.

Therapeutic plasma exchange removes this aged plasma and replaces it with fresh 5% albumin solution, typically over a series of four to six sessions. The result is a measurable reset of the circulating environment: lower inflammatory burden, restored antioxidant capacity, and a reduction in the pro-aging signals that drive cellular deterioration throughout the body.

The Buck Institute Study: A Multi-Omics Approach

If the 2022 GeroScience paper opened the door, a 2025 study from the Buck Institute for Research on Aging walked through it.

Published in Aging Cell, this multi-omics analysis conducted in partnership with the Buck Institute for Research on Aging went significantly deeper. Rather than relying on a handful of epigenetic markers, the research team deployed 36 distinct epigenetic clocks alongside comprehensive proteomic and metabolomic analysis.

The study examined multiple TPE protocols and found that biweekly plasma exchange with IVIG showed the greatest effect, demonstrating an average biological age reduction of approximately 2.61 years. But what made this study particularly important was the breadth of validation: the rejuvenation signal wasn't limited to one clock or one type of biomarker. It appeared consistently across dozens of independent aging measures and multiple molecular platforms.

This level of multi-omics confirmation, from an institution as respected as the Buck Institute, moved the finding from “promising preliminary evidence” to something the longevity medicine field could no longer overlook.

What This Means for Patients

The biological age research has direct implications for how we approach treatment at Global Apheresis.

For patients pursuing longevity, TPE provides a uniquely rapid and systemic reduction in biological age. Unlike the gradual shifts seen with diet or supplements, TPE's impact is immediately measurable across dozens of epigenetic clocks and has been confirmed through the multi-omics validation of the Buck Institute — a level of scientific rigor rarely seen in longevity medicine.

For patients being treated for specific conditions like Alzheimer's, autoimmune disorders, and post-infectious syndromes, the biological age data suggests that the benefits of TPE extend beyond the targeted condition. When we treat an Alzheimer's patient with plasma exchange, we aren't only addressing amyloid and inflammatory proteins relevant to cognitive decline. We are resetting the broader circulating environment in a way that the body recognizes at the epigenetic level.

This may help explain what Dr. Kiprov has observed clinically for years: patients who come in for one condition often report improvements that go well beyond their primary diagnosis.

The Research Continues

Dr. Kiprov's partnership with the Buck Institute remains active. The 2025 Aging Cell publication represents the beginning of a broader research program examining the systemic effects of plasma exchange on aging biology: which biomarkers respond most dramatically, how long the rejuvenation effect persists, and what treatment frequency optimizes long-term outcomes.

At Global Apheresis, we are in the rare position of operating at the intersection of clinical practice and active research. The protocols we use with patients today are informed by published, peer-reviewed science. The data we generate in our clinic feeds directly back into the next generation of studies.

For patients considering therapeutic plasma exchange for longevity, this means you aren't choosing between clinical care and cutting-edge science. At Global Apheresis, they are the same thing.